Biomarkers in Geographic Atrophy Progression

In an interview with MedPageToday, Talisa E. de Carlo Forest, MD, assistant professor of ophthalmology at the University of Colorado School of Medicine says, “Now that we have our first generation of therapies to slow the rate of progression of GA, it is more important than ever to understand who may most benefit from these treatments. The treatments require an office visit for injection into the eye every 1-2 months and therefore are not risk-free and can be time and resource consuming.”